Atai Life Sciences N.V. (ATAI)

Market Cap	343.20M
Revenue (ttm)	314,000
Net Income (ttm)	-40.22M
Shares Out	167.41M
EPS (ttm)	-0.25
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,173,475
Open	2.170
Previous Close	2.130
Day's Range	2.020 - 2.285
52-Week Range	1.025 - 2.850
Beta	0.98
Analysts	Strong Buy
Price Target	11.25 (+448.78%)
Earnings Date	May 13, 2024

About ATAI

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 18, 2021
• Employees: 83
• Stock Exchange: NASDAQ
• Ticker Symbol: ATAI

Financial Performance

In 2023, ATAI's revenue was $314,000, an increase of 34.76% compared to the previous year's $233,000. Losses were -$40.22 million, -73.60% less than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for ATAI stock is "Strong Buy." The 12-month stock price forecast is $11.25, which is an increase of 448.78% from the latest price.

Price Target

$11.25

(448.78% upside)

Analyst Consensus: Strong Buy